Fennec Pharma
Highly Engaged Employees
Manufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
68 Tw Alexander Research Triangle Park D...Phone Number
(919) 636-4530Website
www.fennecpharma.comRevenue
$44.6 MillionStock Symbol
FENCIndustry
About Fennec Pharma
Fennec Pharma Org Chart
Is Fennec Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Fennec Pharma has new funding data
Fennec Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Fennec Pharma had a recent Job posting/layoffs
Check out if Fennec Pharma is spiking on competitors!
Check if Fennec Pharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Fennec Pharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Fennec Pharma
Product Launch: Get notified when Fennec Pharma launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Fennec Pharma as Masked Content
Find 3 more new buyers
Compare Similar Companies to Fennec Pharma
Compare insights from companies similar to Fennec Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Fennec Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Fennec Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Fennec Pharma.
Fennec Pharma financials insights
Gather financial insights about Fennec Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Private Equity
$45M
Fennec Pharma Tech Stack
A closer look at the technologies used by Fennec Pharma
Most Recent Scoops
Fennec Pharma News & Media
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of stock option awards (“Stock Options”) to purchase an aggregate of 50,000 of the Company’s common shares to three new non-executive employees of the Company with a grant date of May 18, 2026Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
FENNEC PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Top Manufacturing Companies
Frequently Asked Questions Regarding Fennec Pharma
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina, that specializes in developing and commercializing therapies to reduce the risk of hearing loss caused by platinum-based chemotherapy, particularly in pediatric patients. Its flagship product, PEDMARK®, a formulation... Read More